Matthew William Burnell Trotter,Alberto Risueno-Perez,Michael Pourdehnad,Anita Gandhi,Patrick Hagner
申请号：
US15273205
公开号：
US20170088901A1
申请日:
2016.09.22
申请国别(地区):
US
年份:
2017
代理人:
摘要：
In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A； or a stereoisomer thereof； or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof； or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A； or a stereoisomer thereof； or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof； or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.
